Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Intern Med ; 283(2): 190-199, 2018 02.
Article in English | MEDLINE | ID: mdl-29098731

ABSTRACT

BACKGROUND: Early detection of autoimmune Addison's disease (AAD) is important as delay in diagnosis may result in a life-threatening adrenal crisis and death. The classical clinical picture of untreated AAD is well-described, but methodical investigations are scarce. OBJECTIVE: Perform a retrospective audit of patient records with the aim of identifying biochemical markers for early diagnosis of AAD. MATERIAL AND METHODS: A multicentre retrospective study including 272 patients diagnosed with AAD at hospitals in Norway and Sweden during 1978-2016. Scrutiny of medical records provided patient data and laboratory values. RESULTS: Low sodium occurred in 207 of 247 (84%), but only one-third had elevated potassium. Other common nonendocrine tests were largely normal. TSH was elevated in 79 of 153 patients, and hypoglycaemia was found in 10%. Thirty-three per cent were diagnosed subsequent to adrenal crisis, in whom electrolyte disturbances were significantly more pronounced (P < 0.001). Serum cortisol was consistently decreased (median 62 nmol L-1 [1-668]) and significantly lower in individuals with adrenal crisis (38 nmol L-1 [2-442]) than in those without (81 nmol L-1 [1-668], P < 0.001). CONCLUSION: The most consistent biochemical finding of untreated AAD was low sodium independent of the degree of glucocorticoid deficiency. Half of the patients had elevated TSH levels. Only a minority presented with marked hyperkalaemia or other nonhormonal abnormalities. Thus, unexplained low sodium and/or elevated TSH should prompt consideration of an undiagnosed AAD, and on clinical suspicion bring about assay of cortisol and ACTH. Presence of 21-hydroxylase autoantibodies confirms autoimmune aetiology. Anticipating additional abnormalities in routine blood tests may delay diagnosis.


Subject(s)
Addison Disease/diagnosis , Early Diagnosis , Addison Disease/blood , Addison Disease/complications , Adolescent , Adult , Aged , Biomarkers/blood , Blood Glucose/metabolism , Child , Child, Preschool , Female , Humans , Hydrocortisone/blood , Hyperkalemia/etiology , Hypoglycemia/etiology , Hyponatremia/etiology , Male , Middle Aged , Potassium/blood , Retrospective Studies , Sodium/blood , Thyrotropin/blood , Young Adult
2.
J Clin Endocrinol Metab ; 98(4): E753-60, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23436915

ABSTRACT

BACKGROUND: Bone mineral density (BMD) in adult patients with Prader-Willi syndrome (PWS) might be low due to high bone turnover. OBJECTIVES: The objective of the study was to investigate bone mass in a group of adult PWS subjects and study the effects of GH treatment on BMD and markers of bone turnover. DESIGN: Forty-six adults with genetically verified PWS were randomized to GH or placebo for 12 months, followed by open prospective GH for 24 additional months. BMD at the lumbar spine (LS) L1-4, the total hip, and the total body was assessed by dual-energy x-ray absorptiometry at baseline and every 12th month thereafter. Markers of bone turnover were measured at baseline and at the end of the controlled study. RESULTS: In this cohort of adult subjects with PWS, baseline BMD was reduced in all compartments compared with the reference (Z-scores). Men had lower Z-scores BMD than women in LS and total body (P < .05). With 12 months of GH, LS-BMD was significantly reduced compared with placebo. No changes in BMD were observed with continuous GH treatment for 24 months. The bone formation markers increased with GH therapy compared with placebo, whereas the resorption marker did not change. CONCLUSIONS: Adult PWS subjects, especially the men, have low bone mass that was not improved with GH treatment for 2 years. Because PWS subjects are short, BMD might be underestimated and should be adjusted for. Further studies, with adequate GH and sex hormone replacement throughout puberty and early adult life, are needed to better characterize PWS.


Subject(s)
Bone Density/drug effects , Human Growth Hormone/therapeutic use , Prader-Willi Syndrome/drug therapy , Absorptiometry, Photon , Adult , Cohort Studies , Denmark , Female , Human Growth Hormone/pharmacology , Humans , Lumbar Vertebrae/drug effects , Male , Norway , Placebos , Prader-Willi Syndrome/metabolism , Time Factors , Young Adult
3.
Growth Horm IGF Res ; 21(2): 69-75, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21295507

ABSTRACT

OBJECTIVE: The goal of growth hormone (GH) replacement is to improve quality of life (QoL) and prevent the long-term complications of GH deficiency (GHD). Thirty-nine patients with adult-onset GH deficiency (AOGHD) who had originally participated in a randomized placebo-controlled crossover study involving treatment with either GH or placebo for nine months were enrolled in an open, 33-month follow-up study of the effects on QoL as well as bone and metabolic parameters. METHODS: GH replacement was dosed individually to obtain IGF-I concentrations that were within the upper part of the normal range for age (mean+1SD). The variables were assessed on five occasions during the study. RESULTS: QoL, as assessed by the sum scores of HSCL-58, AGHDA, physical activity (KIMS question 11) and the dimension vitality in SF-36, improved. Markers of bone formation and resorption remained increased throughout the study period. Bone mineral area (BMA), bone mineral content (BMC) and bone mineral density (BMD) increased in both the lumbar (L2-L4) spine and total body. BMC and BMD increased in the femur. Hypogonadal women however, showed reduced bone mass during the study period. The changes in body fat mass (BFM) and lean body mass (LBM) were sustained throughout the long-term treatment (BFM -2.18 (+/-4.87) kg LBM by 2.01(+/-3.25) kg). Low-density lipoprotein cholesterol (LDL-C) levels were reduced by 0.6 (+/-1.1) mmol/l, and high-density lipoprotein cholesterol (HDL-C) levels increased by 0.2 (+/-0.3) mmol/l. No changes were observed in body weight, fasting total cholesterol, triglycerides, HbA1c and plasma glucose. Mean fasting insulin levels increased significantly from 110 pmol/l to 159 pmol/l, p<0.02. CONCLUSION: Long-term replacement of growth hormone in patients with AOGHD induces favorable effects on QoL as well as bone and metabolic parameters. An increase in insulin levels is also noteworthy.


Subject(s)
Hormone Replacement Therapy , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Quality of Life , Adult , Body Composition/physiology , Bone Density/physiology , Bone and Bones/metabolism , Female , Follow-Up Studies , Human Growth Hormone/administration & dosage , Humans , Lipids/blood , Male , Time
4.
Nord Med ; 108(12): 330-1, 1993.
Article in Norwegian | MEDLINE | ID: mdl-8272398

ABSTRACT

Clinical handbooks and procedure descriptions have been suggested as a way to improve the practical part of the medical education in Norway, but experience with books of this type is scarce, and the applicability of the model has been questioned. This paper reports a questionnaire survey among Norwegian medical students who have had hands-on experience with such a book throughout their student practice. The book apparently has been used, and no serious criticism has been put forward. It is an obvious sine qua non that such a book is used with proper care, and that the cooperation with senior doctors on duty is maintained.


Subject(s)
Clinical Competence , Internship and Residency , Manuals as Topic , Humans , Norway , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...